SLSheng-Rong Li

Sheng-Rong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sheng-Rong Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Chang-Yu Yan

    School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei 230012, China

    1 shared publication
  • Cheng-Jun Zhu

    The First Affiliated Hospital of Jinan University, Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of the Chinese Ministry of Education, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, and The Sixth Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China

    1 shared publication
  • Dan-Hua Lu

    The First Affiliated Hospital of Jinan University, Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of the Chinese Ministry of Education, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, and The Sixth Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China

    1 shared publication
  • Feng Huang

    College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Kunming 650500, People's Republic of China; School of Chinese Materia Medica and Yunnan Key Laboratory of Southern Medicinal Utilization, Yunnan University of Chinese Medicine, Kunming 650500, People's Republic of China

    1 shared publication
  • Genlong Jiao

    Dongguan Key Laboratory of Central Nervous System Injury and Repair, Department of Orthopedic Surgery, The Sixth Affiliated Hospital of Jinan University, Jinan University, Dongguan 523573, China

    1 shared publication
  • Hai-Biao Gong

    The First Affiliated Hospital of Jinan University, Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of the Chinese Ministry of Education, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, and The Sixth Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Catalyst-Free Late-Stage Functionalization to Assemble α-acyloxyenamide Electrophiles for Selectively Profiling Conserved Lysine Residues

    by Yuanyuan Zhao, Kang Duan, Youlong Fan, Shengrong Li, Liyan Huang, Zhengchao Tu, Jing Yang, Pinghua Sun, Yi Tan, Ke Ding, et al.

    Covalent probes coupled with chemical proteomics represent a powerful method for investigating small molecule and protein interactions. However, the creation of a reactive warhead within various ligands to form covalent probes has been a major obstacle. Herein, we report a convenient and robust process to assemble a unique electrophile, an α-acyloxyenamide, through a one-step late-stage coupling reaction. This procedure demonstrates remarkable tolerance towards other functional groups and facilitates ligand-directed labeling in proteins of interest. The reactive group has been successfully incorporated into a clinical drug targeting the EGFR L858R mutant, erlotinib, and a pan-kinase inhibitor. The resulting probes have been shown to be able to covalently engage a lysine residue proximal to the ATP-binding pocket of the EGFR L858R mutant. A series of active sites, and Mg2+, ATP-binding sites of kinases, such as K33 of CDK1, CDK2, CDK5; K278 of PAK2 and K270 of KPYM were detected. This is the first report of engaging these conserved catalytic lysine residues in kinases with covalent inhibition. Further application of this methodology to natural products has demonstrated its success in profiling ligandable conserved lysine residues in whole proteome. These findings offer insights for the development of new targeted covalent inhibitors (TCIs) and pave the way for future advancements in drug discovery and chemical proteomics.

  • Open Access

    Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons

    by Jie Sun, Xiao-Min Lin, Dan-Hua Lu, Meng Wang, Kun Li, Sheng-Rong Li, Zheng-Qiu Li, Cheng-Jun Zhu, Zhi-Min Zhang, Chang-Yu Yan, et al.

    Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the gradual loss of midbrain dopaminergic neurons in association with aggregation of α-synuclein. Oxidative damage has been widely implicated in this disease, though the mechanisms involved remain elusive. Here, we demonstrated that preferential accumulation of peroxidized phospholipids and loss of the antioxidant enzyme glutathione peroxidase 4 (GPX4) were responsible for vulnerability of midbrain dopaminergic neurons and progressive motor dysfunctions in a mouse model of PD. We also established a mechanism wherein iron-induced dopamine oxidation modified GPX4, thereby rendering it amenable to degradation via the ubiquitin-proteasome pathway. In conclusion, this study unraveled what we believe to be a novel pathway for dopaminergic neuron degeneration during PD pathogenesis, driven by dopamine-induced loss of antioxidant GPX4 activity.